{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-23-045834","form_type":"8-K","ticker":"JSPR","cik":"0001788028","company_name":"Jasper Therapeutics, Inc.","filed_at":"2023-06-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.589397+00:00","generated_at":"2026-06-14T08:26:23.031679+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Jasper Therapeutics receives FDA guidance for briquilimab in CSU; IND filing and first patient dose expected in H2 2023","bullets":["FDA provided guidance on the proposed program for briquilimab for chronic spontaneous urticaria (CSU).","Company expects to file IND for briquilimab in CSU and dose first patient in H2 2023.","Jasper will continue engagement with FDA toward IND submission and launch of CSU clinical trial.","Updated corporate presentation posted on company website as of June 2, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-23-045834","json":"https://secwatch.observer/filing/0001213900-23-045834.json","markdown":"https://secwatch.observer/filing/0001213900-23-045834.md","text":"https://secwatch.observer/filing/0001213900-23-045834.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023045834/0001213900-23-045834-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1788028/000121390023045834/ea179684-8k_jasperthera.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T08:26:23.031679+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}